C Ch ha an ng ge es s i in n sse er ru um m n ne eo op pt te er ri in n a an nd d s se er ru um m b be et ta a 2 2 --m mi ic cr ro og gl lo ob bu ul li in n i in n s su ub bj je ec ct ts s w wi it th h l lu un ng g i in nf fe ec ct ti io on ns s Thirty HIV-positive subjects with PCP, 9 HIV-positive patients with bacterial pneumonia, and 16 HIV-negative patients with bacterial pneumonia were investigated. Thirty eight asymptomatic HIV-positive subjects and 48 healthy blood donors were used as controls.The HIV-positive patients with PCP and the HIV-positive subjects with bacterial pneumonia had significantly and similarly elevated levels of neopterin and β 2 -microglobulin in the acute stage. In the weeks before the acute stage of PCP, neopterin and β 2 -microglobulin had been increasing. After start of treatment, serum neopterin declined significantly, whilst serum β 2 -microglobulin remained elevated. The HIV-negative patients with bacterial pneumonia had significantly increased serum concentrations of both markers in the acute stage, and had decreasing serum concentrations in the weeks after treatment.We conclude that neither neopterin nor β 2 -microglobulin seem to be of value in distinction between PCP and bacterial pneumonia in HIV-positive subjects. In the HIV-positive patients, neopterin may correlate partly with the clinical activity of PCP, whilst serum β 2 -microglobulin may remain elevated after PCP, despite treatment and recovery. The elevated level may, in part, be due to repeated infections and progression to acquired immune deficiency syndrome (AIDS). In the HIV-negative patients with pneumonia both parameters seem to correlate with disease activity and recovery.